Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

MISSISSAUGA, ON, March 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM II, a clinical trial which is being planned to support an application for U.S. market approval of the Celacade(TM) System for the treatment of patients with New York Heart Association (NYHA) Class II heart failure.

The Company announced in December that the FDA was examining its internal jurisdiction over Vasogen's Celacade System in the context of a newly issued draft guidance document to assess whether this document was relevant to Celacade. Previously, the FDA's Center for Devices and Radiological Health (CDRH) acted as lead reviewer of Celacade, with input from the Center for Biologics Evaluation and Research (CBER). The FDA has confirmed that Celacade will remain regulated as a medical device; however, CBER will be the lead reviewer of the Celacade technology, with CDRH providing input. The transition process from CDRH to CBER is now complete.

As part of the transition, on February 29, CDRH communicated to the Company that they now disagree with the use of a Bayesian approach because of a concern with recruiting a heterogeneous study population between ACCLAIM and ACCLAIM II. This is contrary to the FDA's original communication to Vasogen recommending a Bayesian study design, and, as part of its ongoing informal dialogue, the Company plans to provide the FDA with its position regarding the ACCLAIM II study population.

"The FDA's comments with respect to utilizing a Bayesian approach for the design of ACCLAIM II are surprising," commented Chris Waddick, President and CEO of Vasogen. "Our immediate focus will be to engage in discussions with the FDA to clarify their position on the proposed ACCL
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... DOR BioPharma, Inc. (DOR or the ... announced today that investigators at the Fred Hutchinson Cancer ... in Bone Marrow Transplantation in which they ... or BDP) decreases non-infectious inflammation of the lung in ...
... 29 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the ... and Earth Technology Development Corp. Ltd.,("China RainEarth") attended the ... , A good marketing strategy ... products. In the forum, participants explored various marketing,strategies and ...
... Associates | Architects ( www.kornberg.com ) has been ... Cognitive & Neurobiological Imaging Center. Ken Kornberg, president and ... Stanford University since 1980 and has completed 20 ... the two-story, 32,000 square-foot office building for the Stanford Linear ...
Cached Biology Technology:DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6RainEarth (RNER) Continues to Expand its Marketing Force in China 2RainEarth (RNER) Continues to Expand its Marketing Force in China 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
(Date:4/14/2014)... scientists are continuing to unravel the molecular changes that ... respiratory infections. , When the bacterium Yersinia pestis enters ... is 100 percent fatal if untreated. The way in ... and kills people in a matter of days has ... study demonstrating that the presence of a protein called ...
(Date:4/14/2014)... families face the decision of whether to get ... the decision can be even more challenging. Now, ... ownership decisions in families of children with autism ... the parents reported the benefits of dog ownership ... children to learn responsibility. , "Children with autism ...
(Date:4/14/2014)... feel when an elevator zips you up multiple floors in ... carried you all the way up to the top of ... That,s similar to what many fish experience when they travel ... change in pressure is simply too big, too fast, and ... in the March issue of the journal Fisheries , ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... trial called the "Evaluate the Clinical use of vitamin ... Angela Cheung and colleagues at the University of Toronto ... did not protect against age-related bone mineral density (BMD) ... Medicine , the findings also suggest that vitamin K1 ...
... University Medical Center has suggested an entirely new way to explain ... have debated for the past 100 years about why -- when ... object -- the flash is perceived to lag behind the position ... to present a completely different way of thinking about how this ...
... their chimpanzee relatives, bonobo societyin which females enjoy a ... image. While chimpanzee males frequently band together to hunt ... to restrict what meat they do eat to forest ... to a study, reported in the October 14th issue ...
Cached Biology News:Duke team explains a longtime visual puzzler in new way 2Despite 'peacenik' reputation, bonobos hunt and eat other primates too 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: